Key words: Batimastat (BB-94), cell cycle perturbations, metalloproteinase inhibitor Matrix metalloproteinases (MMP) are a class of enzymes responsible for matrix degradation. They play a role in metastasis formation by facilitating tumor cell invasion and in angiogenesis by mediating the remodeling and penetretion of extracellular matrix by new capillaries [1, 2] . Therefore a MMP inhibitor should have the potential to block and inhibit tumor progression by preventing local invasion and inhibiting tumor angiogenesis. Batimastat (BB-94) is the first synthetic MMP inhibitor which was investigated in clinic. Preclinically, it has been shown to inhibit metastasis of the murine B16 melanoma [3] , reduce the growth of experimental murine hemangioma [4] and the metastatic spread of human colon cancer in nude mice [5] . In nude mice bearing human ovarian carcinoma (HOC) BB-94 reduces ascites and prolongs survival by changing the tumor stromal composition, forming an avascular tumor [6] . Although the preclinical data suggest that BB-94 inhibits extracellular matrix breakdown and neovascularization its antitumor activity might also be due to a direct effect on tumor cell growth. To investigate this, we evaluated whether BB-94 had effected the proliferation and cell cycle phase distribution of Skov-3 human ovarian cancer cells.
Matrix metalloproteinases (MMP) are a class of enzymes responsible for matrix degradation. They play a role in metastasis formation by facilitating tumor cell invasion and in angiogenesis by mediating the remodeling and penetretion of extracellular matrix by new capillaries [1, 2] . Therefore a MMP inhibitor should have the potential to block and inhibit tumor progression by preventing local invasion and inhibiting tumor angiogenesis. Batimastat (BB-94) is the first synthetic MMP inhibitor which was investigated in clinic. Preclinically, it has been shown to inhibit metastasis of the murine B16 melanoma [3] , reduce the growth of experimental murine hemangioma [4] and the metastatic spread of human colon cancer in nude mice [5] . In nude mice bearing human ovarian carcinoma (HOC) BB-94 reduces ascites and prolongs survival by changing the tumor stromal composition, forming an avascular tumor [6] . Although the preclinical data suggest that BB-94 inhibits extracellular matrix breakdown and neovascularization its antitumor activity might also be due to a direct effect on tumor cell growth. To investigate this, we evaluated whether BB-94 had effected the proliferation and cell cycle phase distribution of Skov-3 human ovarian cancer cells.
The clonogenic inhibitory effect of BB-94 on Skov-3 cells was evaluated by a standard clonogenic assay [7] . BB-94, kindly provided by British Biotech Pharmaceuticals Ltd., UK, was dissolved in ethanol. Continuous exposure to 10, 15 or 30 uM for 72 hours inhibited of clonogenicity of Skov-3 cells by about 30%. Shorter exposure times (24 or 48 hours) caused no significant inhibition. Exposure from 96 to 144 h reduced the clonogenicity to about 50% (P < 0.01 Mann-Whitney test). No differences were found between 96-, 120-and 144-hour treatment (Figure 1) .
The antiproliferative effect of BB-94 was also confirmed in other human cancer cell lines (e.g., human MOLT-4 leukemia) (data not shown).
The cell cycle phase perturbations induced by 10 uM BB-94 were evaluated by biparametric bromodeoxyuridine/DNA (BrdUrd/DNA) flow cytometric analysis [8] . BrdUrd was given to the cells for 48 hours (corresponding to two doubling times of the cells) at different intervals during treatment with BB-94. BB-94 did not affect the incorporation of BrdUrd up to 72-hour treatment. All the BB-94 treated cells were BrdUrd positive and therefore cycling. A small fraction of G o /G! BrdUrd negative cells, about 4% of the whole population, was detected after 96-hour BB-94 treatment. At 144-hour BrdUrd/DNA analysis showed a 50% of BrdUrd-negative cells which were blocked in the Go/G! phase of the cell cycle. Also, the majority of the BrdUrd-positive cells were blocked in the G 0 /Gi phase of the cell cycle.
Most literature on BB-94 focuses on its anti-angiogenetic properties [1, 2, 4, 9] . The present study shows that BB-94 also has some growth inhibitory effects on cancer cells. After prolonged exposure 50% of treated cells were blocked in the Go/Gi phase of the cell cycle. This effect was seen at concentrations achievable in ascites of ovarian cancer patients treated with BB-94 (British Biotech personal communiction). The effect is reversible as cells progress through the cell cycle after drug removal. The possibility that inhibition of MMP causes an effect on cell growth had been previously suggested by other authors and showed that overexpression of the endogenous MMP inhibitor TIMP-1 can reduce cell proliferation [10, 11] .
The mechanism of the cell cycle blockade by BB-94 still needs to be investigated but it is not related to p53 expression as Skov-3 cells do not express p53. The finding that BB-94 causes a G 0 /Gi block must be born in mind in planning combinations of BB-94 with others anticancer drugs. Whether this effect is peculiar to BB-94 or is common to any MMP inhibitors is currently being investigated.
